GEP20043267B - Adenosine Receptor Antagonists, Methods of Making and Using the Same - Google Patents
Adenosine Receptor Antagonists, Methods of Making and Using the SameInfo
- Publication number
- GEP20043267B GEP20043267B GEAP20006495A GEAP2000006495A GEP20043267B GE P20043267 B GEP20043267 B GE P20043267B GE AP20006495 A GEAP20006495 A GE AP20006495A GE AP2000006495 A GEAP2000006495 A GE AP2000006495A GE P20043267 B GEP20043267 B GE P20043267B
- Authority
- GE
- Georgia
- Prior art keywords
- making
- methods
- same
- receptor antagonists
- adenosine receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
Abstract
1. Technical Result Increase in treatment efficiency. 2. Essence A compounds of Formula (I), wherein R1, R2, R5 , X1, X2, Z have the values indicated in the description. Adenosine A1 antagonists can be useful in the prevention and/or treatment of numerous diseases, including cardiac and circulatory disorders, degenerative disorders of the central nervous system, respiratory disorders, etc. 3. Field of Application Medicine.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16528399P | 1999-11-12 | 1999-11-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
GEP20043267B true GEP20043267B (en) | 2004-06-25 |
Family
ID=22598257
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GEAP20006495A GEP20043267B (en) | 1999-11-12 | 2000-11-13 | Adenosine Receptor Antagonists, Methods of Making and Using the Same |
Country Status (33)
Country | Link |
---|---|
US (4) | US6605600B1 (en) |
EP (2) | EP1775297A3 (en) |
JP (1) | JP2003513976A (en) |
KR (1) | KR100845488B1 (en) |
CN (1) | CN1187354C (en) |
AT (1) | ATE353328T1 (en) |
AU (1) | AU784528B2 (en) |
BG (1) | BG106693A (en) |
BR (1) | BR0015540A (en) |
CA (1) | CA2390590C (en) |
CY (1) | CY1106560T1 (en) |
CZ (1) | CZ20021615A3 (en) |
DE (1) | DE60033310T2 (en) |
DK (1) | DK1230241T3 (en) |
EA (1) | EA010260B1 (en) |
EE (1) | EE200200248A (en) |
ES (1) | ES2281367T3 (en) |
GE (1) | GEP20043267B (en) |
HK (1) | HK1049153B (en) |
HU (1) | HUP0203371A3 (en) |
IL (1) | IL149486A0 (en) |
IS (1) | IS6380A (en) |
MX (1) | MXPA02004795A (en) |
NO (1) | NO20022237L (en) |
NZ (2) | NZ519427A (en) |
PL (1) | PL198156B1 (en) |
PT (1) | PT1230241E (en) |
SK (1) | SK6622002A3 (en) |
TR (1) | TR200301062T2 (en) |
UA (1) | UA77937C2 (en) |
WO (1) | WO2001034604A2 (en) |
YU (1) | YU33702A (en) |
ZA (1) | ZA200203702B (en) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI229674B (en) | 1998-12-04 | 2005-03-21 | Astra Pharma Prod | Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses |
WO2001034604A2 (en) * | 1999-11-12 | 2001-05-17 | Biogen, Inc. | Adenosine receptor antagonists and methods of making and using the same |
MEP42208A (en) * | 1999-11-12 | 2011-02-10 | Biogen Idec Inc | Polycycloalkylpurines as adenosine receptor antagonists |
UA84404C2 (en) * | 2002-06-12 | 2008-10-27 | Байоджен Айдек Ма Инк. | Method of treating ischemia reperfusion injury using adenosine receptor antagonists |
US20040106797A1 (en) * | 2002-07-19 | 2004-06-03 | Pascal Druzgala | Novel xanthines having adenosine A1-receptor antagonist properties |
US20040229901A1 (en) * | 2003-02-24 | 2004-11-18 | Lauren Otsuki | Method of treatment of disease using an adenosine A1 receptor antagonist |
BRPI0409307A (en) * | 2003-04-14 | 2006-04-25 | Pfizer Prod Inc | 3-azabicyclo [3.2.1] octane derivatives |
NZ543109A (en) * | 2003-04-25 | 2008-06-30 | Novacardia Inc | Method of improved diuresis in individuals with impaired renal function |
US7247639B2 (en) * | 2003-06-06 | 2007-07-24 | Endacea, Inc. | A1 adenosine receptor antagonists |
JP2009528389A (en) * | 2006-03-02 | 2009-08-06 | シーブイ・セラピューティクス・インコーポレイテッド | A2A adenosine receptor antagonist |
WO2007117549A2 (en) * | 2006-04-06 | 2007-10-18 | Novacardia, Inc. | Co-administration of adenosine a1 receptor antagonists and anticonvulsants |
ES2525076T3 (en) | 2006-05-19 | 2014-12-17 | Abbvie Bahamas Ltd. | Derivatives of azabicyclic alkanes substituted with condensed bicycloheterocycles active in the CNS |
EP2035009A1 (en) * | 2006-06-16 | 2009-03-18 | Novacardia, Inc. | Prolonged improvement of renal function comprising infrequent administration of an aa1ra |
US20090197900A1 (en) * | 2007-03-29 | 2009-08-06 | Howard Dittrich | Methods of treating heart failure and renal dysfunction in individuals with an adenosine a1 receptor antagonist |
US20080242684A1 (en) * | 2007-03-29 | 2008-10-02 | Howard Dittrich | Methods of administration of adenosine a1 receptor antagonists |
US20090228097A1 (en) * | 2008-03-07 | 2009-09-10 | Abbott Cardiovascular Systems Inc. | A1 Adenosine Receptor Antagonist-Coated Implantable Medical Device |
CN114790164B (en) | 2021-08-13 | 2022-12-27 | 苏州璞正医药有限公司 | Substituted isoindoline-1,3-diketone PDE4 inhibitor and pharmaceutical application thereof |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3155664A (en) * | 1959-11-13 | 1964-11-03 | Endo Lab | Derivatives of theophylline |
DE8817122U1 (en) | 1988-12-22 | 1993-02-04 | Boehringer Ingelheim Kg, 6507 Ingelheim, De | |
JPH06102662B2 (en) * | 1989-09-01 | 1994-12-14 | 協和醗酵工業株式会社 | Xanthine derivative |
US5290782A (en) | 1989-09-01 | 1994-03-01 | Kyowa Hakko Kogyo Co., Ltd. | Xanthine derivatives |
EP0423805B1 (en) | 1989-10-20 | 2000-08-23 | Kyowa Hakko Kogyo Kabushiki Kaisha | Condensed purine derivatives |
DE4019892A1 (en) | 1990-06-22 | 1992-01-02 | Boehringer Ingelheim Kg | New xanthine derivs. are selective A1 adenosine antagonists - useful for treating CNS disorders (e.g. senile dementia) and heart and circulation disorders |
CA2061544A1 (en) | 1991-02-25 | 1992-08-26 | Fumio Suzuki | Xanthine compounds |
EP0541120B1 (en) | 1991-11-08 | 1999-05-26 | Kyowa Hakko Kogyo Co., Ltd. | Xanthine derivatives for the treatment of dementia |
US5336769A (en) | 1992-02-17 | 1994-08-09 | Kyowa Hakko Kogyo Co., Ltd. | Xanthine derivatives |
US5342841A (en) | 1992-03-12 | 1994-08-30 | Kyowa Hakko Kogyo Co., Ltd. | Xanthine derivatives |
TW252044B (en) | 1992-08-10 | 1995-07-21 | Boehringer Ingelheim Kg | |
WO1994016702A1 (en) | 1993-01-26 | 1994-08-04 | Kyowa Hakko Kogyo Co., Ltd. | Remedy for irregular bowel movement |
US5395836A (en) | 1993-04-07 | 1995-03-07 | Kyowa Hakko Kogyo Co., Ltd. | 8-tricycloalkyl xanthine derivatives |
US5446046A (en) * | 1993-10-28 | 1995-08-29 | University Of Florida Research Foundation | A1 adenosine receptor agonists and antagonists as diuretics |
AU7675598A (en) | 1997-06-16 | 1999-01-04 | Kyowa Hakko Kogyo Co. Ltd. | Hepatic edema remedy |
AU7675498A (en) | 1997-06-16 | 1999-01-04 | Kyowa Hakko Kogyo Co. Ltd. | Preventive and remedy for drug-induced nephropathy |
DE19816857A1 (en) * | 1998-04-16 | 1999-10-21 | Boehringer Ingelheim Pharma | Novel adenosine antagonists useful in treatment of e.g. neurodegenerative, pulmonary, renal and cardiovascular disorders |
EP0955301A3 (en) * | 1998-04-27 | 2001-04-18 | Pfizer Products Inc. | 7-aza-bicyclo[2.2.1]-heptane derivatives, their preparation and use according to their affinity for neuronal nicotinic acetylcholine receptors |
AU4396899A (en) | 1998-07-02 | 2000-01-24 | Kyowa Hakko Kogyo Co. Ltd. | Remedies for diabetes |
MEP42208A (en) * | 1999-11-12 | 2011-02-10 | Biogen Idec Inc | Polycycloalkylpurines as adenosine receptor antagonists |
WO2001034604A2 (en) * | 1999-11-12 | 2001-05-17 | Biogen, Inc. | Adenosine receptor antagonists and methods of making and using the same |
-
2000
- 2000-11-13 WO PCT/US2000/031100 patent/WO2001034604A2/en active IP Right Grant
- 2000-11-13 CA CA2390590A patent/CA2390590C/en not_active Expired - Fee Related
- 2000-11-13 EE EEP200200248A patent/EE200200248A/en unknown
- 2000-11-13 GE GEAP20006495A patent/GEP20043267B/en unknown
- 2000-11-13 EA EA200200562A patent/EA010260B1/en not_active IP Right Cessation
- 2000-11-13 JP JP2001536551A patent/JP2003513976A/en active Pending
- 2000-11-13 CN CNB008161984A patent/CN1187354C/en not_active Expired - Fee Related
- 2000-11-13 ES ES00983698T patent/ES2281367T3/en not_active Expired - Lifetime
- 2000-11-13 EP EP06026675A patent/EP1775297A3/en not_active Withdrawn
- 2000-11-13 SK SK662-2002A patent/SK6622002A3/en unknown
- 2000-11-13 AU AU20421/01A patent/AU784528B2/en not_active Ceased
- 2000-11-13 UA UA2002064854A patent/UA77937C2/en unknown
- 2000-11-13 PL PL356044A patent/PL198156B1/en not_active IP Right Cessation
- 2000-11-13 IL IL14948600A patent/IL149486A0/en unknown
- 2000-11-13 BR BR0015540-3A patent/BR0015540A/en not_active Application Discontinuation
- 2000-11-13 MX MXPA02004795A patent/MXPA02004795A/en active IP Right Grant
- 2000-11-13 AT AT00983698T patent/ATE353328T1/en active
- 2000-11-13 EP EP00983698A patent/EP1230241B1/en not_active Expired - Lifetime
- 2000-11-13 PT PT00983698T patent/PT1230241E/en unknown
- 2000-11-13 CZ CZ20021615A patent/CZ20021615A3/en unknown
- 2000-11-13 YU YU33702A patent/YU33702A/en unknown
- 2000-11-13 NZ NZ519427A patent/NZ519427A/en not_active IP Right Cessation
- 2000-11-13 KR KR1020027006022A patent/KR100845488B1/en not_active IP Right Cessation
- 2000-11-13 DE DE60033310T patent/DE60033310T2/en not_active Expired - Lifetime
- 2000-11-13 HU HU0203371A patent/HUP0203371A3/en unknown
- 2000-11-13 US US09/711,554 patent/US6605600B1/en not_active Expired - Fee Related
- 2000-11-13 TR TR2003/01062T patent/TR200301062T2/en unknown
- 2000-11-13 DK DK00983698T patent/DK1230241T3/en active
-
2002
- 2002-05-09 ZA ZA200203702A patent/ZA200203702B/en unknown
- 2002-05-10 NO NO20022237A patent/NO20022237L/en not_active Application Discontinuation
- 2002-05-10 IS IS6380A patent/IS6380A/en unknown
- 2002-05-13 BG BG106693A patent/BG106693A/en unknown
- 2002-12-23 HK HK02109300.4A patent/HK1049153B/en not_active IP Right Cessation
-
2003
- 2003-06-12 US US10/461,534 patent/US20030225038A1/en not_active Abandoned
- 2003-09-01 NZ NZ527918A patent/NZ527918A/en not_active IP Right Cessation
-
2005
- 2005-05-13 US US11/128,550 patent/US20050222179A1/en not_active Abandoned
-
2007
- 2007-05-04 CY CY20071100590T patent/CY1106560T1/en unknown
- 2007-07-27 US US11/829,269 patent/US20080004293A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GEP20043303B (en) | Polycycloalkylpurines as Adenosine Receptor Antagonists | |
GEP20043267B (en) | Adenosine Receptor Antagonists, Methods of Making and Using the Same | |
NZ508808A (en) | 4-benzyl piperidine alkylsulfoxide heterocycles and their use as subtype-selective NMDA receptor antagonists | |
SI0725779T1 (en) | ||
NZ522326A (en) | Adenosine A2A receptor antagonists | |
AU2001236904A1 (en) | Deep brain stimulation system for the treatment of parkinson's disease or other disorders | |
UA66825C2 (en) | Azapolycyclic compounds condensed with aryl | |
BG104599A (en) | Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas | |
NZ329627A (en) | 8-Heterocyclically substituted 1,3,8-triaza-spiro[4.5]decan-4-ones | |
IL112539A0 (en) | Pyrimidine derivatives and their preparation | |
AP2000001947A0 (en) | Novel crystalline forms of an antiviral benzidazole compound. | |
NO20002702L (en) | thienopyrimidine | |
HK1044333A1 (en) | Chemokine receptor antagonists and methods of use therefor | |
MXPA04000886A (en) | DERIVATIVES OF TRIAZOLYL-IMIDAZOPYRIDINE AND OF THE TRIAZOLYLPURINES USEFUL AS LIGANDS OF THE ADENOSINE A2a. | |
GEP20033081B (en) | Pharmaceutical Agents for Treatment of Parkinson's Disease, ADFD and Microadenomas | |
BG106171A (en) | Compositions and uses of et743 for treating cancer | |
WO2001018004A3 (en) | PYRAZOLO[4,3-d]PYRIMIDINES | |
BG105689A (en) | Utilization of pyrimidine derivatives for preventing and treating cerebral ischaemia | |
GR3036458T3 (en) | 4-imidomethyl-1- 2'phenyl-2'oxoethyl-] piperidines as serotonin 5ht 2?-antagonists, their preparation and use in therapy. | |
WO2000071520A3 (en) | Aryl substituted alkylamines capable of activating nicotinic cholinergic receptors | |
AU655958B2 (en) | Use of quisqualate-receptor antagonists for treating Parkinson's disease | |
MX9604762A (en) | Novel sulfonamides and process for the preparation thereof. | |
MXPA04004826A (en) | Chemokine receptor antagonists and methods of use thereof. | |
NZ533358A (en) | 3,4-Dihydro-1H-isoquinolin-2-yl-derivatives for use as NK2 receptor antagonists | |
MY105555A (en) | Heterocyclicguanidines as 5ht 3 antagonists. |